Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)
PCT, a NeoStem Company, Presented Lovo(R) Cell Processing System Data at IBC Life Sciences' Commercialization of Cell, Gene & Immunotherapies Conference
GlobeNewswire - Mon Dec 15, 6:39AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, and Progenitor Cell Therapy, LLC ("PCT"
NBS: 3.27 (+0.02)
NeoStem's Subsidiary, Progenitor Cell Therapy, Earns AABB Re-Accreditation for Its Allendale, NJ Manufacturing Facility
GlobeNewswire - Mon Dec 08, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
NBS: 3.27 (+0.02)
Insider Trading Alert - UGI, NBS And MACK Traded By Insiders
at The Street - Fri Dec 05, 10:15AM CST
Stocks with insider trader activity include UGI, NBS and MACK
MACK: 10.91 (+0.36), UGI: 38.27 (+0.64), NBS: 3.27 (+0.02)
NeoStem, Inc. - "Initial Trial Results of PreSERVE AMI: The Meaningful Clinical Relevance of the Data"
ACCESSWIRE - Tue Dec 02, 7:33AM CST
New York, NY / ACCESSWIRE / December 2, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Robin L. Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)
NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences
GlobeNewswire - Mon Dec 01, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
NBS: 3.27 (+0.02)
NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014
GlobeNewswire - Wed Nov 26, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that it will host a Key Opinion Leader event webcast on Monday, December 1, 2014 from 4:30 to 5:30 PM EST.
NBS: 3.27 (+0.02)
NeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine
GlobeNewswire - Tue Nov 25, 6:30AM CST
NeoStem, Inc. (Nasdaq:NBS) announced today that Dr. Robert Preti, the Company's Chief Scientific Officer and President of its subsidiary, Progenitor Cell Therapy ("PCT"
NBS: 3.27 (+0.02)
NeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial
GlobeNewswire - Fri Nov 21, 2:09PM CST
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics, announced on November 17 initial positive data from its 161 patient Phase 2 PreSERVE AMI (or acute myocardial infarction) clinical trial.
NBS: 3.27 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST
LEJU: 10.72 (+0.28), GEOS: 26.42 (-0.61), LXRX: 0.90 (+0.02), OTIV: 1.71 (unch), GME: 33.39 (-1.24), ARUN: 18.45 (+0.40), NBS: 3.27 (+0.02), PHMD: 1.46 (-0.03), AMDA: 0.64 (-0.01), CANF: 3.70 (+0.01), MOLG: 2.92 (+0.03), WAIR: 14.20 (unch), EDAP: 1.97 (+0.01), FWM: 2.80 (-0.03), GERN: 3.06 (+0.05), OCRX: 5.77 (+0.02), NGVC: 26.39 (+0.09), SFUN: 7.17 (-0.03), EJ: 7.48 (+0.17), BGI: 1.66 (+0.20)
Hot Stock: Neostem, Shares Drop 8.8% (NBS)
Comtex SmarTrend(R) - Fri Nov 21, 10:36AM CST
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 8.8% to $4.06 on 1.7x average daily volume. Thus far today, Neostem has traded 701,000 shares, vs. average volume of 415,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.7%) and underperformed the S&P 500 (-8.8% to the S&P's 0.7%) during today's trading.
NBS: 3.27 (+0.02)
NeoStem: Changing The Goalposts Midgame And A Potentially Biased Analyst
Bleecker Street Research - Seeking Alpha - Fri Nov 21, 8:30AM CST
On November 14, Maxim Group analyst Jason Kolbert put out a bullish note on NeoStem, Inc. (NASDAQ: NBS ) in front of Phase 2 data. The note combined with apparent market enthusiasm for this data helped propel shares up 40% in two weeks before the...
NBS: 3.27 (+0.02)
NeoStem's NBS10 And Data That Matters To Regulators
Steven Giardino - Seeking Alpha - Fri Nov 21, 6:30AM CST
On Monday evening, NeoStem (NASDAQ: NBS ) reported interim data on their double-blind placebo-controlled 161-patient Ph II study testing NBS10 in patients that had experienced acute myocardial infarction (AMI). With the exception of a noticeable...
BAX: 74.45 (-0.04), NBS: 3.27 (+0.02)
Wound Care Market by Type (Traditional (Wound Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, Hydrocolloids, Alginate, Collagen), Active (Artificial Skin & Skin Substitutes), Pressure Relief Devices, NPWT) - Global Forecast to 201
PR Newswire - Wed Nov 19, 7:58PM CST
The global wound care market is expected to reach $18.3 billion by 2019 from $15.6 billion in 2014, growing at a CAGR of 3.2% from 2014 to 2019. The global wound care market is categorized on the basis of product and geography. The active wound care market is expected to register the highest growth rate in the wound care market during the forecast period, owing to the continuous launch of new and advanced products.
NBS: 3.27 (+0.02)
Neostem (NBS): Today's Weak On High Volume Stock
at The Street - Wed Nov 19, 9:02AM CST
Trade-Ideas LLC identified Neostem (NBS) as a weak on high relative volume candidate
NBS: 3.27 (+0.02)
NeoStem, Inc. - "Encouraging Findings from PreSERVE AMI"
ACCESSWIRE - Wed Nov 19, 7:44AM CST
New York, NY / ACCESSWIRE / November 19, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Visionary Officer and Chief Medical Officer of Progenitor Cell Therapy, Dr. Andrew L. Pecora. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)
NeoStem, Inc. - "PreSERVE AMI Phase 2 Results"
ACCESSWIRE - Tue Nov 18, 12:38PM CST
New York, NY / ACCESSWIRE / November 18, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer, Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 3.27 (+0.02)
NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data
at The Street - Tue Nov 18, 11:40AM CST
Shares of NeoStem (NBS) plunged in late morning trading Monday after the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.
NBS: 3.27 (+0.02)
NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study
at The Street - Tue Nov 18, 9:16AM CST
Using stem cells to repair damaged hearts is a great story, but proof remains elusive.
NBS: 3.27 (+0.02)